Overview

Evaluating Contrave for Weight Maintenance in Adults With BMI >= 27 Kg/m2, After 6 Month Behaviour Modification Program.

Status:
Not yet recruiting

Trial end date:
2022-11-30

Target enrollment:

Participant gender:

Summary

Contrave (naltrexone HCl and bupropion HCl) extended-release tablet is an approved drug and indicated to be used with a low calorie diet and increased physical activity for chronic weight management in obese adults (BMI 30 Kg/m2 or greater) or overweight adults (BMI 27 Kg/m2 or greater) with at least one weight related condition such as hypertension or diabetes. Presently we do not have any evidence for the use of Contrave for weight maintenance. The purpose of this study is to demonstrate that in participants who have ≥ 5% weight loss following the completion of a behaviour modification program with meal replacements, Contrave combined with usual care (dietary and behaviour counselling) will significantly improve maintenance of weight loss and promote further weight loss, compared to placebo with usual care.

Phase:

Phase 4

Details

Lead Sponsor:

St. Joseph's Healthcare Hamilton

Collaborator:

Bausch Health, Canada Inc.

Treatments:

Bupropion
Bupropion hydrochloride, naltrexone hydrochoride drug combination
Naltrexone